Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 20 (Bloomberg) -- BioLineRx Ltd. tumbled the most on record after an experimental treatment for schizophrenia failed to help patients in a mid-stage clinical trial, prompting the Israeli drugmaker to end development of the compound.

BioLine, based in Jerusalem, plunged 53 percent to $1.80 in New York, the lowest price since July 2011, when the shares were listed in the U.S. The Bloomberg Israel-US Equity Index of the biggest Israeli companies in the U.S. rose for the first time in four days, adding 1 percent.

The treatment, BL-1020, didn’t meet the trial’s main goal of improving cognitive function compared with risperidone, a generic drug, BioLine said in a statement. The American depositary receipts had gained 51 percent this year through yesterday. Shares in Tel Aviv dropped 52 percent to 6.82 shekels, or $1.85 today.

“For the stock price to be cut in half, in our view, seems excessive,” Raghuram Selvaraju, an analyst at New York-based Aegis Capital Corp., said in a phone interview. He cut his share-price estimate today by 36 percent to $7 and kept a buy rating on BioLine. “All the institutional investors I spoke with thought it would fail.”

The biopharmaceutical company said in the statement that research and development costs will drop this year and in part of 2014 by about $6 million to $7 million.

Schizophrenia is a disabling brain disorder, affecting about 1 percent of Americans, according to the National Institute of Mental Health.

To contact the reporter on this story: Leslie Picker in New York at

To contact the editor responsible for this story: Emma O’Brien at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.